Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DA-1726 · 1 trial · 1 indication
AEs, SAEs, TEAEs and AEs leading to treatment discontinuation.
| Arm | Type | Description |
|---|---|---|
| Part 1 - Single Ascending Dose | ACTIVE_COMPARATOR | Single doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting. |
| Part 2 - Multiple Ascending Dose | PLACEBO_COMPARATOR | Multiple doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting. |
| Part 3 - Titration | ACTIVE_COMPARATOR | Multiple doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting, using either 1-step or 2-steps titration. |
| Name | Type | Description |
|---|---|---|
| DA-1726 | DRUG | Active |
| Placebo to DA-1726 | DRUG | Placebo |
Inclusion Criteria: 1. Willing and able to provide informed consent prior to initiation of any study specific procedures/activities. 2. Males and females ≥18 to \<=65 years of age, at the time of signing informed consent, who have been diagnosed with obesity, defined by BMI. 3. Except for obesity, ...
Top 20 of 32 competitors
DA-1726 is an investigational small molecule being developed for the treatment of obesity. It is currently in Phase 1 clinical development, with an ongoing first-in-human study in subjects with obesity who are otherwise healthy.
DA-1726 targets the GLP1R and GCGR receptors. By acting on these receptors, it is designed to address metabolic conditions, specifically obesity. The drug is a small molecule, and its mechanism involves modulation of these receptor pathways.
DA-1726 is being developed by MetaVia Inc., a biopharmaceutical company. The company is conducting clinical trials for this drug candidate, which is currently in Phase 1 development for the treatment of obesity.
DA-1726 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate the drug in individuals with obesity.
DA-1726 is being studied in a Phase 1 clinical trial with the identifier NCT06252220. This first-in-human study is recruiting 139 participants with obesity in the United States. The trial is randomized, double-blind, and placebo-controlled, enrolling adults aged 18 years and older.